

Mini-Future 2x Long

Linked to the Swiss Market Index (SMI®)



Issued by UBS AG


SVSP Product Type: Various Leverage (2199)
 Valor: 10192262; SIX Symbol: SMI2L

Final Terms

1. Description of the Product

About Mini-Future 2x Long

Mini-Future 2x Long are designed to provide **two times (200%) the performance** of the underlying **on a daily basis** (adjusted by fees, expenses and dividends). Therefore, if the underlying increases (decreases) by 1% between two consecutive trading days, the Mini-Future 2x Long will increase (decrease) by approximately 2%.



* adjusted by the management fee, financing expenses and dividend payouts

Due to the compounding effect, Mini-Future 2x Long are very unlikely to provide the exact multiple (200%) of the Underlying's performance over periods longer than one day. In extreme cases and/or over longer investment periods results can even differ significantly. For more information, see the Product Description.

Mini-Future 2x Long are suitable only for sophisticated investors who have a clear understanding of the risks and benefits of leverage.

Information on Underlying

Underlying(s)	Swiss Market Index Bloomberg: SMI / Valor: 998089
---------------	---

Product Details

Security Numbers	Valor: 10192262 / ISIN: CH0101922620
SIX Symbol	SMI2L
Issue Size	50'000 units (with reopening clause)
Issue Price	CHF 100
Settlement Currency	CHF
Leverage Factor	2
Management Fee	0.6% p.a.

Contact: UBS AG, P.O. Box, 8098 Zurich
 Institutional Investors: +41-44-239 68 00*
 Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Dates

Launch Date	06 July 2009
Pricing Date ("Pricing")	06 July 2009
First SIX Trading Date (anticipated)	27 August 2009
Payment Date (Issue Date)	13 July 2009
Expiration Date ("Expiry")	Open End
Effective Exercise Day	means the day when either the Investor's Exercise Right or the Issuer's Call Right becomes effective.
Redemption Date	means the 5 th Business Day following the Effective Exercise Date. In case this date is not a Business Day the next following Business day will apply.

Redemption

The Investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency, equivalent to the **Issue Price multiplied by all daily Mini-Future 2x Long returns since issue date** (where each daily Mini-Future 2x Long return is calculated by two times the leveraged daily performance of the underlying, adjusted by the management fee, financing expenses and dividend payouts). If ever the underlying decreases by approximately 50% or more in one single business day, the respective daily factor will be set to 0, rendering the product worthless, but it will NOT redeem early. The calculation is according to the following formula:

$$\text{Issue Price} * \prod_{i=0}^n \left[\text{Max} \left(1 + \text{LF} * \frac{(l_{i+1} - l_i) + (k * \text{Div}_i)}{l_i} - \text{FC}_i - \text{MF}_i; 0 \right) \right]$$

where:

n = Number of exchange business days since Pricing Date
 LF = Leverage Factor
 l = Official closing level of the Underlying, as determined by the Index Sponsor
 k = Dividend tax factor (set between zero and one and determined by the Calculation Agent in its reasonable discretion)
 Div = Applicable Gross Dividends
 FC = Financing expenses and borrow costs (if applicable), as reasonably determined by the Calculation Agent *
 MF = Management Fee*

*All charges are accruing daily from the Pricing Date to the Effective Exercise Day and calculated on an Actual/360 basis.

Applicable Gross Dividends An amount in the Settlement Currency determined by the Calculation Agent at its reasonable discretion, on basis of dividend or similar payments to be distributed to the holders of the Underlying whereby the ex-date of such payment on the Related Exchange is between the current and the next following business day.

Contact: UBS AG, P.O. Box, 8098 Zurich
 Institutional Investors: +41-44-239 68 00*
 Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Product Structure

With Mini-Future 2x Long investors can participate in two times (200%) the performance of the Underlying on a daily basis (adjusted by the management fee, financing expenses and dividend payouts).

Over a period of more than one day the return of Mini-Future 2x Long is likely to differ from two times (200%) the index's performance over that same period. This is due to the compounding effect of a daily resetting mechanism, where the notional amount is reset on a daily basis to two times (200%) the value of the Mini-Future 2x Long.

In extreme scenarios and/or over longer investment periods the divergence between the return of Mini-Future 2x Long and two times (200%) the index's performance can be significant.

The following hypothetical examples (excluding management fee, financing expenses and dividend payouts) illustrate the compounding effect on the performance of Mini-Future 2x Long over periods longer than one day :

Example 1: Low volatility

	Value Underlying	Return Underlying	Return Mini-Future 2x Long	Value Mini-Future 2x Long
Start	100.0%			100.00%
Day 1	101.0%	1.0%	2.0%	102.00%
Day 2	102.0%	1.0%	2.0%	104.04%
Day 3	103.0%	1.0%	2.0%	106.12%
Day 4	104.1%	1.0%	2.0%	108.24%
Day 5	105.1%	1.0%	2.0%	110.41%
Total Return	5.1%			10.41%

Example 2: High volatility

	Value Underlying	Return Underlying	Return Mini-Future 2x Long	Value Mini-Future 2x Long
Start	100.0%			100.0%
Day 1	104.5%	4.5%	9.0%	109.0%
Day 2	100.3%	-4.0%	-8.0%	100.3%
Day 3	104.8%	4.5%	9.0%	109.3%
Day 4	100.6%	-4.0%	-8.0%	100.6%
Day 5	105.2%	4.5%	9.0%	109.6%
Total Return	5.2%			9.6%

The examples demonstrate that high volatility of the Underlying will cause the effect of compounding to be more pronounced, while lower volatility of the Underlying will produce a more muted effect.

General Information

Issuer	UBS AG, Zurich
Issuer Rating	Aa2 Moody's (under review for possible downgrade) / A+ S&P's / A+ Fitch
Lead Manager	UBS AG, Zurich (UBS Investment Bank)
Calculation Agent	UBS AG, Zurich
Paying Agent	UBS AG, Zurich
Related Exchange	The exchanges on which components comprising the Underlying are traded, as determined by the Calculation Agent from time to time.
Index Sponsor	SIX Swiss Exchange
Listing	SIX Listing will be applied for
Minimum Investment	1 Unit
Minimum Trading Lot	1 Unit

Contact:	UBS AG, P.O. Box, 8098 Zurich		
Institutional Investors:	+41-44-239 68 00*	Internet:	www.ubs.com/keyinvest
Private Investors:	derivatives@ubs.com		

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Issuer Call Right	The Issuer has the quarterly right, on each 06 July, 06 October, 06 January, 06 April, for the first time on 06 July 2010 ("Notice Date"), to call the Mini-Future 2x Long for early redemption for a value equal to Redemption (as described herein), effective 3 months after the "Notice Date" has been published ("Effective Exercise Day") to that effect (in case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies). The Mini-Future 2x Long will be redeemed on the Redemption Date.
Investor Exercise Right	In addition to the possibility to sell the Mini-Future 2x Long at any time, each Investor has a quarterly right, on each 06 July, 06 October, 06 January, 06 April 06 July, for the first time on 06 July 2010 ("Exercise Date") to exercise the Mini-Future 2x Long (notice to be received no later than 10.00 am CET on the relevant Exercise Date) for the value equal to Redemption (as described herein) at the time of the exercise. The exercise will become effective as of close of business on the relevant Exercise Date (in case that any of the dates is not an Exchange Business Day, the next following Exchange Business Day applies). The Mini-Future 2x Long will be redeemed on the Redemption Date.
Clearing	SIX SIS, Euroclear, Clearstream (booked at SIX SIS AG)
Form of deed	Book-entry Security
Governing Law / Jurisdiction	Swiss / Zurich
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.

Tax Treatment Switzerland

Swiss Federal Stamp Duty	For Swiss Stamp Duty purpose, the product is treated as analogous to a share. Therefore, secondary market transactions are in principle subject to Swiss Stamp Duty (TK23).
Swiss Federal Income Tax	For private investors with tax domicile in Switzerland, in line with common practice of the Swiss Federal Tax Administration regarding Direct Federal Tax, an interest component will be taxable at the Redemption Date (Issuer Call Right & Investor Exercise Right). This interest component will be determined by the issuer based on the length of the tenor of the product and will be reported in the year of redemption to the Swiss Federal Administration which in turn will publish it in the respective list of tax ("Kursliste"). In contrast, any capital gains which accrued during the tenor of the product from selling it are not taxable. Capital losses which accrued during the tenor of the product from either selling it or redeeming it are not deductible from taxable income.
Swiss Withholding Tax	The product is not subject to the Swiss withholding tax.
EU Savings Tax	For Swiss paying agents, the product is not subject to the EU Savings tax

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

Contact: UBS AG, P.O. Box, 8098 Zurich
 Institutional Investors: +41-44-239 68 00*
 Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Product Documentation

The Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', as amended from time to time ("General Terms and Conditions") shall form the entire documentation for this Product ("Product Documentation"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. Furthermore, the Final Terms shall serve as and fulfil the requirements of a 'Simplified Prospectus' in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). In the event that the Product is listed (see above item 'Listing' under 'General Information'), the Product Documentation will be amended in accordance with the listing requirements of the relevant Exchange.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, the Product Documentation is available on the internet at www.ubs.com/keyinvest.

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Investdata. In addition, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised and regulated by the Financial Services Authority (FSA) and its Jersey Branch by the Jersey Financial Services Commission (JFSC).

2. Prospects of Profits and Losses

Market Expectation	Investors in this Product expect a positive Performance of the Underlying over the life of the Product.
Risk Tolerance	Investors in this product should be experienced investors and familiar with derivative products, leverage and stock and/or commodity markets. The Investors must be willing to make an investment with a disproportionately higher yield potential than a direct investment in the underlying strategy. This increased yield potential comes at an increased unlimited downside risk. The Investors do not require capital protection.
Profit Potential	The Investors may profit from an increased participation in the underlying strategy.
Loss Potential	The Investors may lose some or all of the investment.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 68 00*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank *pari passu* with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

Secondary Market

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the General Terms and Conditions".

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 68 00*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Index Disclaimers

Swiss Market Index

These securities are not in any way sponsored, endorsed, sold or promoted by the SIX Swiss Exchange and the SIX Swiss Exchange makes no warranty or representation whatsoever, express or implied, either as to the results to be obtained from the use of the SMI® index (the "Index") and/or the figure at which the said Index stands at any particular time on any particular day or otherwise. The Index is compiled and calculated solely by the Swiss Exchange SIX. However, the Swiss Exchange shall not be liable (whether in negligence or otherwise) to any person for any error in the Index and the SIX Swiss Exchange shall not be under any obligation to advise any person of any error therein.

®SWX®, SWX Swiss Exchange®, SPI®, Swiss Performance Index (SPI)®, SPI EXTRA®, SMI®, Swiss Market Index®, (SMI)®, SMIM®, SMI MID (SMIM)®, SMI Expanded®, SXI®, SXI LIFE SCIENCES®, SXI Bio+Medtech®, SBI®, SBI Swiss Bond Index®, VSMI®, SWX Immobilienfonds Index® and SWX Quotematch® are trademarks that have been registered in Switzerland and/or abroad by SWX Swiss Exchange Their use in subject to a licence.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 68 00*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - For EEA jurisdictions (EU member states plus Norway, Iceland and Liechtenstein) that have implemented the EU Prospectus Directive ("EU-PD"), the Product Documentation for this Product DOES NOT QUALIFY as a prospectus published in accordance with the requirements of the EU-PD. Unless and until a prospectus has been published in accordance with the requirements of the EU-PD, this Product may not be offered or sold in EEA jurisdictions that have implemented the EU-PD other than 1) in minimum denominations of, or total consideration per Investor of at least, EUR 50,000 (or equivalent in other currencies) or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 offerees that are not Qualified Investors per EEA jurisdiction. A "Qualified Investor" is a legal entity that (i) is authorised or regulated to operate in the financial markets or has the sole purpose to invest in securities; or (ii) meets two of the following three criteria (as shown in its last annual or consolidated accounts): (a) an average number of at least 250 employees during the last financial year; (b) a total balance sheet of more than EUR 43,000,000; and (c) an annual net turnover of more than EUR 50,000,000.

For EEA jurisdictions that have not implemented the EU-PD, sales must be in compliance with the law of that jurisdiction.

Hong Kong - This Product may not be offered or sold in Hong Kong.

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Cap. 289) of

Singapore ("SFA"), (ii) to a relevant person, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- (a) a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor,

the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired the securities under Section 275 of the SFA except:

- (1) to an institutional investor (for corporations, under Section 274 of the SFA) or to a relevant person, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than S\$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section 275 of the SFA;
- (2) where no consideration is or will be given for the transfer; or
- (3) where the transfer is by operation of law.

UK - For the purposes of non-discretionary accounts, this Product should not be sold with a consideration of less than 50,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 68 00*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG